Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. develops oncology immunotherapies as a clinical-stage biotechnology company with American depositary shares traded under PPBT. Its recurring updates center on CAPTN-3, a platform of capped or masked tri-specific antibodies designed to target tumor-associated antigens while engaging both T cells and NK cells in the tumor microenvironment.
Company news commonly covers preclinical data, toxicology and manufacturing work for IM1240, the 5T4-targeting lead CAPTN-3 antibody, and IM1305, the TROP2-targeting development candidate. Other recurring themes include oncology research collaborations, scientific advisory activity, financial results, ADR and capital-structure actions, Nasdaq listing compliance, and governance updates.
Purple Biotech (NASDAQ/TASE: PPBT) reported Q1 2026 results and pipeline progress. New IM1240 tri-specific antibody data showed anti-tumor activity across all tested, treatment-resistant patient-derived samples. The company formed a CAPTN-3 Scientific Advisory Board and expanded its Converge Bio AI collaboration.
R&D expenses were $1.2M and G&A $1.0M. Adjusted operating loss and adjusted net loss were each $2.1M. Finance income, net was $2.2M, leading to a reported net loss of $0.1M. Cash and deposits totaled $6.4M, with runway expected into 2027.
Purple Biotech (NASDAQ: PPBT) reported preclinical IM1240 data showing anti-tumor activity across seven patient-derived tumor samples.
IM1240 is a conditionally activated capped-CD3 × 5T4 × NKG2A tri-specific antibody; the NKG2A arm enhanced activity, and NSCLC explants showed induction of mature tertiary lymphoid structures with increased CD8 and NK cells.
Purple Biotech (NASDAQ: PPBT) announced the formation of a Scientific Advisory Board to support advancement of its CAPTN-3 tri‑specific antibody platform toward clinical-stage immunotherapy development. The SAB includes experts with direct experience in NK and T‑cell engagers and in the clinical development of approved T‑cell therapies.
The board will advise on translational science, NK and T cell biology, and clinical strategy as Purple advances CAPTN-3 toward first-in-human studies.
Purple Biotech (NASDAQ: PPBT) announced a collaboration with Converge Bio on March 25, 2026 to apply proprietary generative AI to accelerate and optimize its next-generation tri-specific antibody platform for oncology. The partnership targets faster discovery, improved developability, and expanded capability against solid-tumor targets.
The collaboration will integrate Converge Bio's AI-driven molecule design with Purple Biotech's CAPTN-3 conditional activation technology to generate optimized T cell engagers and additional high-quality candidates.
Purple Biotech (NASDAQ: PPBT) announced it regained compliance with Nasdaq Listing Rule 5550(a)(2) after its American Depositary Shares maintained a minimum closing bid of $1.00 or more for at least 10 consecutive business days, a condition met on March 13, 2026. The company is now compliant with Nasdaq listing standards.
The company is a clinical-stage immunotherapy developer advancing lead candidates IM1240 and IM1305 and maintaining other clinical-stage assets pending partnering or investment.
Purple Biotech (NASDAQ/TASE: PPBT) announced that Gil Efron will step down as CEO effective August 2026 for health reasons and will transition to lead corporate development while remaining on the Board.
The Board has begun a formal CEO search; the company highlighted continued focus on the CAPTN-3 tri-specific antibody platform and an orderly leadership transition.
Purple Biotech (NASDAQ:PPBT) reported Q4 and full-year 2025 results highlighting advancement of its CAPTN-3 tri-specific antibody program. Lead molecules IM1240 and IM1305 showed positive preclinical efficacy, expanded toxicology window and commercially viable manufacturing yield.
Key figures: cash $9.5M (Dec 31, 2025) with runway into 2027, $20.5M impairment for CM24/NT219, and $26.4M net loss for 2025.
Purple Biotech (NASDAQ: PPBT) will change its American Depositary Share (ADS) ratio from 1 ADS = 200 ordinary shares to 1 ADS = 2,000 ordinary shares, effective at the opening of trading on or about March 2, 2026.
The action is a one-for-ten reverse ADS split aimed at regaining compliance with Nasdaq's $1.00 minimum bid price requirement; ADSs continue to trade under the ticker PPBT and a new CUSIP 74638P307 was assigned.
Purple Biotech (NASDAQ: PPBT) reported that its tri-specific antibody IM1240 from the CAPTN-3 platform completed a non-human primate toxicology study showing an expanded therapeutic window.
Key findings: IM1240 was tolerated at doses up to 300-fold higher than a non-capped comparator (IM1222) with significantly reduced immune-related toxicity and only modest cytokine release. IM1240 also showed a favorable PK profile with increased systemic exposure, dose-proportional AUC and Cmax, and a prolonged circulating half-life attributed to albumin incorporation and capping design. Efficacy in tumor-bearing mice occurred at exposures below those in the Study. The company plans regulatory submission toward first-in-human studies in H2 2026.
Purple Biotech (NASDAQ: PPBT) reported positive preclinical results for its CAPTN-3 tri-specific antibody platform presented at ESMO IO 2025. Two candidates, IM1240 (capped-CD3×5T4×NKG2A) and IM1305 (capped-CD3×TROP2×NKG2A), showed strong anti-tumor activity across multiple solid-tumor models, including activity in PD-1–resistant ex-vivo NSCLC and HNSCC samples. Transcriptomic analysis of ~11,000 TCGA samples supported co-expression of NKG2A with 5T4, justifying the NKG2A arm. IM1305 bound TROP2 and NKG2A (EC50 ~2 nM), showed PBMC-mediated killing at EC50 1–5 pM, and induced sustained tumor regression in humanized TNBC mice (p < 0.0001). Company expects IND-enabling progress and key milestones in 2026.